Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
Cellectar Biosciences, Inc.
ClinicalTrials.gov Identifier:
NCT01778088
First received: January 25, 2013
Last updated: February 24, 2014
Last verified: February 2014

January 25, 2013
February 24, 2014
May 2014
June 2014   (final data collection date for primary outcome measure)
Evaluate the 6-month survival rate of subjects receiving I-131-CLR1404 for relapsed glioma [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01778088 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma
A Phase 2a, Multi-Center, Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma

The purpose of this study is to determine the recommended dosing of I-131-CLR1404, a radiolabeled therapy compound, for treating subjects with glioma.

Subjects who meet study entry criteria will receive I-131-CLR1404. For each subject, the study will be conducted in three phases, dosimetric, therapy, and follow-up. In the dosimetric phase, subjects will receive one 5 mCi dose of the study drug and undergo whole body imaging on on the day of infusion and on post-infusion days 2, 3, and 7 for assessment of biodistribution and tumor uptake of I-131-CLR1404. If normal and expected biodistribution are demonstrated, the subject will begin the therapy phase. In the therapy phase, the subjects will receive a dose based on body surface area and may receive additional doses if they meet dosing criteria. After the last treatment dose, subjects will enter the follow-up phase and will be followed monthly.

All subjects will be prescribed thyroid protection medication to be taken 24 hours prior to injection of the dosimetric dose, and continuing for 14 days after the administration of the therapy dose.

Not Provided
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Glioma
Drug: I-131-CLR1404 Injection
Other Name: 18-(p-[I-131]-iodophenyl)octadecyl phosphocholine
Single Group
I-131-CLR1404 Injection
Intervention: Drug: I-131-CLR1404 Injection
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
January 2015
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed high-grade glioblastoma multiforme (GBM)
  • Failed prior therapy with Avastin
  • Radiologic evidence of tumor progression
  • Received at least 45 Gy and no more than 66 Gy prior radiotherapy
  • Ambulatory with an ECOG performance status of 0 to 2 (Appendix C)
  • 18 years of age or older

Exclusion Criteria:

  • Received more than 25% of total bone marrow irradiated, total body or hemi-body irradiation or prior radioisotope therapy (except for benign thyroid disease)
  • Prior radiation therapy or chemotherapy within 4 weeks of start of study
  • Another active medical condition(s) or organ disease(s) that may compromise subject safety or interfere with safety and/or outcome evaluation of study drug
  • Laboratory abnormalities, including but not limited to: WBC < 3000/uL, Absolute neutrophil count < 1500/uL, Platelets < 150,000/uL, Hemoglobin ≤ 9.0 gm/dL, Total bilirubin > 1.5 x upper limit of normal for age, SGOT or SGPT > 3 x upper limit of normal for age if no liver metastases or > 5 x upper limit of normal for age in the presence of liver metastases, Serum creatinine > 1.5 x upper limit of normal for age, 2+ proteinuria or casts indicative of intrinsic renal disease
  • Treatment with investigational drug, investigational biologic, or investigational therapeutic device within 28 days of initiating study treatment
  • Received prior stem cell transplantation
  • Clinically significant cardiac co-morbidities including congestive heart failure (New York Heart Association class III-IV heart disease), left ventricular ejection fraction < 40%, unstable angina pectoris, serious cardiac arrhythmia requiring medication or pacemaker, myocardial infarction within past 6 months
  • Concurrent or recent (within 1 month) use of thrombolytic agents, or full-dose anticoagulants (except to maintain patency of preexisting, permanent indwelling IV catheters).
  • Uncontrolled hypertension as defined by systolic blood pressure > 150 mm/Hg, diastolic blood pressure > 100 mm/Hg or uncontrolled diabetes that would compromise subject safety or interfere with safety and/or outcome evaluation of study drug
  • Major surgery within 4 weeks of enrollment
  • Poor venous access and unable to receive study drug into a peripheral venous catheter
  • Significant traumatic injury within past 4 weeks
  • Ongoing or active infection requiring antibiotics or with fever >38.1º C (>101º F) within 3 days of first scheduled day of dosing
  • Receiving concurrent hemodialysis or peritoneal dialysis
  • Known positive for HIV, Hepatitis C (active, previously treated or both), or is Hepatitis B core antigen positive
  • Pregnant or lactating
  • Hospitalized
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01778088
DCL-13-001
No
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc.
Not Provided
Principal Investigator: Minesh Mehta, M.D., FASTRO University of Marylannd School of Medicine
Cellectar Biosciences, Inc.
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP